BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 233 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,466 | -28.6% | 207,095 | -29.0% | 0.07% | -22.5% |
| Q2 2023 | $2,053 | -5.7% | 291,556 | +11.7% | 0.09% | -13.6% |
| Q1 2023 | $2,177 | +20.1% | 260,986 | +65.2% | 0.10% | +3.0% |
| Q4 2022 | $1,813 | -99.9% | 157,944 | +62.6% | 0.10% | +35.1% |
| Q3 2022 | $1,224,000 | +48.4% | 97,127 | +24.5% | 0.07% | +19.4% |
| Q2 2022 | $825,000 | -25.5% | 77,988 | +14.5% | 0.06% | -15.1% |
| Q1 2022 | $1,108,000 | +298.6% | 68,114 | +239.6% | 0.07% | +108.6% |
| Q4 2021 | $278,000 | -3.5% | 20,056 | 0.0% | 0.04% | -7.9% |
| Q3 2021 | $288,000 | – | 20,056 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |